### Financial Performance Highlights
- Revenue: $1.532 million, with a significant decline of 77.09% year-over-year and a 28.58% decrease quarter-over-quarter. This decline is mainly attributed to reduced commercial activity and ongoing clinical trials.
- Gross Profit: $1.177 million, resulting in a gross profit margin of approximately 76.83%. This suggests strong efficiency in their cost of revenue despite the drop in top-line figures.
- Operating Income: -$19.183 million, showing a continued trend of losses, although the operating loss is slightly better compared to previous quarters.
- Net Income: -$17.875 million, with an EPS of -$0.10, indicating a growing concern over profitability.
- Cash Position: Ended the quarter with $43.1 million in cash and equivalents, down from $26.3 million at the beginning of the period, yet improved compared to $41.3 million at the end of the previous quarter, reflecting a stable cash runway well into 2026.
- Research and Development Spending: Total of $15.403 million, accounting for 28 times more than the revenue generated, highlighting aggressive investments in ongoing clinical studies.